Entries by Citron Research

,

Citron’s Last Word on Valeant

We are Not Dialing Back Our Warning on Valeant … We are Dialing Back the Focus on Citron to Investigate and Report the Vast Spectrum of Claims Now Piling Up Against Valeant. For over 14 years, Citron Research has been uncovering stock fraud and unique angles to stories that have gone either unnoticed or misunderstood by either […]

,

Valeant — Could this be the Pharmaceutical Enron ?

Citron Publishes the Smoking Gun!! Price Target lowered to $50 Just four days ago in the world of Valeant, no one had ever heard of Philidor RX.  Recent concerns about the company focused on its unsavory business practices of massive price raises on pharmaceuticals acquired in a rapid succession of acquisitions, while slashing research and development.  […]

,

TWOU — For-Profit Education with an “F” in Investability

Not Investable — Short Term Price Target $14 ·          2U (NASDAQ:TWOU): It’s NOT really an SaaS company.     In reality, it is a for-profit outsourced online degree provider founded almost eight years ago, yet still generates ~85% of revenues from only 4 clients. ·        Stock irrationally doubled due to economically inconsequential and highly controversial […]

,

Why a Congressional Subpoena to Valeant About Price Gouging on Drugs Should be Granted

The Real Risk to the US Healthcare System is when Health Care Costs are controlled by Hedge Fund Billionaires How Pharmaceutical Pricing Runs Amok While U.S. Taxpayers Are Looted As well as a major threat to the integrity of our entire healthcare system, Valeant (NYSE:VRX) is now the most devious three-cornered tax avoidance scheme we’ve ever seen. […]